AVNS · As filed with the SEC
Avanos Medical balance sheet, by quarter
The statement as Avanos Medical presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED BALANCE SHEETS · USD
| USD | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash and cash equivalents | 65,600,000 | 89,800,000 | 70,500,000 | 90,300,000 | 97,000,000 | 107,700,000 | 89,000,000 | 92,200,000 |
| Accounts receivable, net of allowances | 103,000,000 | 103,800,000 | 111,500,000 | 110,200,000 | 104,800,000 | 132,800,000 | 131,900,000 | 123,000,000 |
| Inventories | 141,300,000 | 148,000,000 | 150,600,000 | 142,700,000 | 138,100,000 | 138,800,000 | 161,900,000 | 163,900,000 |
| Prepaid and other current assets | 15,100,000 | 13,800,000 | 18,800,000 | 12,800,000 | 12,500,000 | 14,100,000 | 15,900,000 | 22,300,000 |
| Assets held for sale | — | — | — | — | — | 0 | 73,900,000 | 72,700,000 |
| Total Current Assets | 325,000,000 | 355,400,000 | 351,400,000 | 356,000,000 | 352,400,000 | 393,400,000 | 472,600,000 | 474,100,000 |
| Property, Plant and Equipment, net | 111,200,000 | 113,400,000 | 115,400,000 | 114,300,000 | 109,800,000 | 110,700,000 | 109,500,000 | 110,700,000 |
| Operating Lease Right-of-Use Assets | 39,300,000 | 27,600,000 | 29,900,000 | 31,100,000 | 32,100,000 | 34,100,000 | 26,500,000 | 29,400,000 |
| Goodwill | 394,000,000 | 394,900,000 | 394,400,000 | 381,200,000 | 455,900,000 | 455,600,000 | 795,100,000 | 794,400,000 |
| Other Intangible Assets, net | 114,700,000 | 117,800,000 | 122,000,000 | 105,400,000 | 107,200,000 | 112,300,000 | 220,100,000 | 226,200,000 |
| Deferred Tax Assets | 33,000,000 | 33,100,000 | 25,300,000 | 25,300,000 | 25,000,000 | 24,900,000 | 6,600,000 | 6,300,000 |
| Other Assets | 32,900,000 | 31,500,000 | 29,300,000 | 25,700,000 | 25,400,000 | 23,200,000 | 25,800,000 | 16,700,000 |
| TOTAL ASSETS | 1,050,100,000 | 1,073,700,000 | 1,067,700,000 | 1,039,000,000 | 1,107,800,000 | 1,154,200,000 | 1,656,200,000 | 1,657,800,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current Liabilities | ||||||||
| Current portion of long-term debt | 10,900,000 | 10,200,000 | 9,400,000 | 9,400,000 | 9,400,000 | 9,400,000 | 9,400,000 | 10,200,000 |
| Current portion of operating lease liabilities | 10,400,000 | 8,200,000 | 9,500,000 | 10,400,000 | 10,400,000 | 10,900,000 | 13,700,000 | 14,400,000 |
| Trade accounts payable | 52,300,000 | 55,500,000 | 54,200,000 | 48,800,000 | 46,000,000 | 54,300,000 | 54,200,000 | 51,400,000 |
| Accrued expenses | 57,600,000 | 91,300,000 | 74,800,000 | 66,000,000 | 71,400,000 | 91,300,000 | 82,700,000 | 79,500,000 |
| Liabilities held for sale | — | — | — | — | — | 0 | 52,900,000 | 52,700,000 |
| Total Current Liabilities | 131,200,000 | 165,200,000 | 147,900,000 | 134,600,000 | 137,200,000 | 165,900,000 | 212,900,000 | 208,200,000 |
| Long-Term Debt | 87,300,000 | 90,300,000 | 93,400,000 | 95,700,000 | 98,000,000 | 125,300,000 | 152,600,000 | 164,900,000 |
| Operating Lease Liabilities | 29,800,000 | 20,400,000 | 21,400,000 | 21,800,000 | 23,100,000 | 24,600,000 | 26,500,000 | 28,800,000 |
| Deferred Tax Liabilities | 5,600,000 | 6,100,000 | 6,300,000 | 6,300,000 | 5,600,000 | 5,500,000 | 23,900,000 | 23,400,000 |
| Other Long-Term Liabilities | 14,100,000 | 13,500,000 | 20,700,000 | 4,300,000 | 4,500,000 | 4,400,000 | 10,600,000 | 10,500,000 |
| Total Liabilities | 268,000,000 | 295,500,000 | 289,700,000 | 262,700,000 | 268,400,000 | 325,700,000 | 426,500,000 | 435,800,000 |
| Stockholders’ Equity | ||||||||
| Preferred stock - $0.01 par value - authorized 20,000,000 shares, none issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Common stock - $0.01 par value - authorized 300,000,000 shares, 46,673,069 outstanding as of March 31, 2026 and 46,456,462 outstanding as of December 31, 2025 | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 |
| Additional paid-in capital | 1,696,000,000 | 1,691,900,000 | 1,690,700,000 | 1,686,900,000 | 1,682,800,000 | 1,678,600,000 | 1,674,700,000 | 1,671,500,000 |
| Accumulated deficit | (774,800,000) | (779,900,000) | (778,600,000) | (777,200,000) | (700,400,000) | (707,000,000) | (309,700,000) | (314,000,000) |
| Treasury stock | (103,600,000) | (102,300,000) | (102,000,000) | (101,900,000) | (101,200,000) | (99,000,000) | (98,900,000) | (98,500,000) |
| Accumulated other comprehensive loss | (36,000,000) | (32,000,000) | (32,600,000) | (32,000,000) | (42,300,000) | (44,600,000) | (36,900,000) | (37,500,000) |
| Total Stockholders’ Equity | 782,100,000 | 778,200,000 | 778,000,000 | 776,300,000 | 839,400,000 | 828,500,000 | 1,229,700,000 | 1,222,000,000 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | 1,050,100,000 | 1,073,700,000 | 1,067,700,000 | 1,039,000,000 | 1,107,800,000 | 1,154,200,000 | 1,656,200,000 | 1,657,800,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.